Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04179175 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04179175 · ClinicalTrials.gov record · last posted 2026-08-21

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Name: Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa — clinical trial record (NCT04179175)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhasePhase 3

SponsorNovartis Pharmaceuticals

Started2020-03-18

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).

Protocol amendment history 1 change detected by DataLookout

2026-08-22

Trial completed

Trial Details

NCT Number	NCT04179175
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Hidradenitis Suppurativa
Enrollment	702 participants
Start Date	2020-03-18
Primary Completion	2023-05-26 (estimated)
Study Completion	2026-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-21